Implitapide is primarily used in the field of medical research and treatment, particularly in the study and management of hyperlipidemia. It functions as a microsomal triglyceride transfer protein (MTP) inhibitor, which plays a crucial role in reducing the synthesis and secretion of lipoproteins in the liver. This mechanism makes it valuable in lowering cholesterol and triglyceride levels in the bloodstream, thereby aiding in the prevention and treatment of cardiovascular diseases. Additionally, Implitapide has been explored for its potential in treating other lipid metabolism disorders, offering insights into therapeutic strategies for conditions associated with abnormal lipid profiles. Its application extends to preclinical studies, where it helps in understanding the biochemical pathways involved in lipid metabolism and the development of novel lipid-lowering agents.